New tracker shows which stocks retail investors are picking

On Thursday the Nasdaq (NDAQ) announced the launch of a Trading Activity Tracker, which follows the trading activity of self-directed retail investors. The new tracker lists stocks and exchange traded funds (ETFs) traded by individuals, as well as buy/sell ratios per ticker. 

A free version of the tracker lists the top 10 most traded stocks and ETFs by share of retail activity, highlighting the previous day’s trading session. 

The tracker uses data from the publicly available Securities Information Processor (SIP) delivered through Nasdaq Data Link, a cloud-based tech platform. 

“Through the expansion of Nasdaq Data Link and its library of datasets, we aim to level the playing field and make data, and by extension, the financial markets, more transparent and accessible to all,” said Oliver Albers, senior vice president and head of data. 

The trading information dates back to 2016 and is available up to the present day. It only provides information on individual stocks and ETFs, not cryptocurrencies. 

Individual investing has boomed during the pandemic, giving rise to new crop of retail investors participating in the public markets.

Time spent in front of a computer, large amounts of liquidity in the markets, and zero-commission trading has contributed to a new and young population of individual investors. A number of them began trading in the public markets in 2020.

In this photo illustration a Nasdaq logo is display on a smartphone screen and a pencil in Athens, Greece on November 8, 2021. (Photo by Nikolas Kokovlis/NurPhoto via Getty Images)

In this photo illustration a Nasdaq logo is display on a smartphone screen and a pencil in Athens, Greece on November 8, 2021. (Photo by Nikolas Kokovlis/NurPhoto via Getty Images)

Read the latest financial and business news from Yahoo Finance

Follow Yahoo Finance on Twitter, Instagram, YouTube, Facebook, Flipboard, and LinkedIn

Yahoo Finance +

Yahoo Finance +

Next Post

IDEAYA Biosciences, Inc. Reports Third Quarter 2021 Financial Results and Provides Business Update

– Strong balance sheet of ~$386 million cash, cash equivalents and marketable securities is anticipated to fund planned operations into 2025 – Observed IDE397 preliminary clinical activity in early Phase 1 dose escalation cohorts, including pharmacodynamic modulation and tumor shrinkage – Enrolling IDE397 Cohort 5 with no observed drug-related serious […]